NCT02415790View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

112

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions

Healthy Participants

Interventions

DRUG

E2027

Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.

DRUG

E2027 matching placebo

E2027 matching placebo capsule will be administered.

Trial Locations (1)

Unknown

Paraxel International, Glendale

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT02415790 - Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter